Investor relations pageIR page | no data available |
Founding year | no data available |
Headquarter | , , no data available |
Employees | (as per )no data available |
Sector | Biotechnology, HealthcareBiotechnology, Healthcareno data available |
Ticker | XBITno data available |
Financial year endsFY ends | End of Decemberno data available |
Last Closing Price as per Oct 13, 2017, in USD |
4.46n/a |
Market Capitalisation in million USD |
145n/a |
Enterprise Value in million USD |
80n/a |
Common Shares Outstanding as per Jun 30, 2016 |
32,428,676n/a |
Preferred Shares Outstanding as per Jun 30, 2016 |
n/a |
Average Basic Shares Outstanding TTM |
32,236,239n/a |
Average Diluted Shares Outstanding TTM |
n/a |
Index Membership |
n/a
|
Revenues | 0n/a |
Gross Profit | 0n/a |
Operating Income | -47n/a |
EBITDA | -46n/a |
Net Profit | -47n/a |
Cash and Cash Equivalents | 65n/a |
Receivables | 0n/a |
Total Current Assets | 66n/a |
PP&E | 17n/a |
Total Assets | 83n/a |
Accounts Payable | 8n/a |
Current Debt | 0n/a |
Total Current Liabilities | 10n/a |
Long-Term Debt | 0n/a |
Total Liabilities | 10n/a |
Total Equity | 83n/a |
Depreciation & Amortisation | 1n/a |
Change in Working Capital | 5n/a |
Operating Cash Flow | -36n/a |
Net Change in PP&E and Intangibles | -5n/a |
Investing Cash Flow | -17n/a |
Dividends Paid | 0n/a |
Financing Cash Flow | 1n/a |
Total Change in Cash | -53n/a |
Free Cash Flow | -46n/a |
Gross Margin | 0.0%n/a |
Operating Margin | 0.0%n/a |
Net Profit Margin | 0.0%n/a |
Return on Equity | -56.2%n/a |
Return on Assets | -55.8%n/a |
Basic EPS | -1.44n/a |
Diluted EPS | n/a |
Sales per Share | 0.00n/a |
Book Value per Share | 2.57n/a |
FCF per Share | -1.43n/a |
Dividends per Share | 0.00n/a |
Price to Earnings Ratio | -3.09n/a |
Price to Sales Ratio | n/a |
Price to Book Value | 1.74n/a |
Price to Free Cash Flow | -3.11n/a |
EV/EBITDA | -1.73n/a |
EV/Sales | n/a |
Book to Market Value | 0.57n/a |
Current Ratio | 639.2%n/a |
Liabilities to Equity Ratio | 12.6%n/a |
Debt to Assets Ratio | 0.0%n/a |
in million USD | FY '13 | FY '14 | FY '15 |
---|---|---|---|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-38
|
|
-2
|
-7
|
-6
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-8
|
-14
|
-31
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-38
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-37
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-37
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-37
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-37
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-37
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-10
|
-22
|
-37
|
Remarks |
restated on Apr 15, 2016
n/a
calculated values,
|
restated on Apr 15, 2016
n/a
calculated values,
|
restated on Apr 15, 2016
n/a
calculated values,
|
in million USD | FY '13 | FY '14 | FY '15 |
---|---|---|---|
Assets | |||
|
n/a
|
57
|
91
|
|
n/a
|
57
|
91
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
1
|
2
|
|
n/a
|
0
|
2
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
58
|
93
|
|
n/a
|
1
|
10
|
|
n/a
|
1
|
10
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
0
|
0
|
|
n/a
|
1
|
10
|
|
n/a
|
59
|
103
|
Liabilities and owners' equity | |||
|
n/a
|
3
3147000
|
6
6291000
|
|
n/a
|
2
1629000
|
5
4825000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
2
1518000
|
1
1466000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
3
3147000
|
6
6291000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
17000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
17000
|
|
n/a
|
0
0
|
0
17000
|
|
n/a
|
3
3147000
|
6
6308000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
152
152351000
|
234
233902000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
-93
-93168000
|
-131
-130651000
|
|
n/a
|
0
-153000
|
0
-201000
|
|
n/a
|
59
59030000
|
103
103050000
|
|
n/a
|
0
0
|
0
0
|
|
n/a
|
59
59030000
|
103
103050000
|
|
n/a
|
62
62177000
|
109
109358000
|
Remarks | restated on n/a | restated on Apr 15, 2016 n/a | restated on Aug 12, 2016 n/a |
in million USD | FY '13 | FY '14 | FY '15 |
---|---|---|---|
|
-10
|
-22
|
-37
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
1
|
1
|
1
|
|
1
|
7
|
4
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-1
|
2
|
-1
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
-9
|
-12
|
-33
|
|
0
|
-1
|
-2
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
-8
|
|
0
|
0
|
0
|
|
0
|
-1
|
-10
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
12
|
64
|
77
|
|
12
|
64
|
77
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
0
|
0
|
0
|
|
12
|
63
|
77
|
|
3
|
50
|
34
|
|
0
|
0
|
0
|
|
3
|
50
|
34
|
|
0
|
0
|
0
|
|
3
|
50
|
34
|
Remarks |
restated on Apr 15, 2016
n/a
calculated values,
|
restated on Apr 15, 2016
n/a
calculated values,
|
restated on Apr 15, 2016
n/a
calculated values,
|